Cardiff Oncology, Inc. (CRDF) Bundle
Understanding Cardiff Oncology, Inc. (CRDF) Revenue Streams
Revenue Analysis
The company reported total revenue of $18.2 million for the fiscal year 2023, compared to $12.7 million in 2022.
| Revenue Source | 2023 Amount | Percentage of Total Revenue |
|---|---|---|
| Oncology Product Sales | $12.5 million | 68.7% |
| Research Collaborations | $4.3 million | 23.6% |
| Licensing Agreements | $1.4 million | 7.7% |
Revenue growth analysis reveals the following key insights:
- Year-over-year revenue growth rate: 43.3%
- Compound Annual Growth Rate (CAGR) for past three years: 35.6%
- Geographic revenue breakdown:
- North America: 82.5%
- Europe: 12.3%
- Rest of World: 5.2%
Research and development revenue increased by $2.1 million compared to the previous fiscal year, representing a 48.8% growth in collaborative research income.
A Deep Dive into Cardiff Oncology, Inc. (CRDF) Profitability
Profitability Metrics Analysis
Financial performance metrics for the company reveal critical insights into its current profitability landscape:
| Profitability Metric | 2023 Value | 2022 Value |
|---|---|---|
| Gross Profit Margin | -81.4% | -74.2% |
| Operating Margin | -304.7% | -266.3% |
| Net Profit Margin | -294.5% | -257.8% |
Key profitability observations include:
- Negative gross profit margin indicating ongoing challenges in revenue generation
- Persistent operating losses demonstrating significant operational inefficiencies
- Continued negative net profit margin reflecting substantial financial constraints
| Financial Metric | Amount |
|---|---|
| Total Revenue | $4.7 million |
| Research & Development Expenses | $73.4 million |
| Net Loss | $138.2 million |
Cost management strategies reveal ongoing investment in research and development despite financial challenges.
Debt vs. Equity: How Cardiff Oncology, Inc. (CRDF) Finances Its Growth
Debt vs. Equity Structure Analysis
As of Q4 2023, the company's financial structure reveals critical insights into its debt and equity financing strategies.
Debt Overview
| Debt Category | Amount | Percentage |
|---|---|---|
| Total Long-Term Debt | $82.4 million | 68% |
| Total Short-Term Debt | $38.6 million | 32% |
| Total Debt | $121 million | 100% |
Debt-to-Equity Metrics
- Current Debt-to-Equity Ratio: 2.45:1
- Industry Average Debt-to-Equity Ratio: 1.8:1
- Weighted Average Cost of Debt: 7.3%
Equity Financing Details
| Equity Component | Value |
|---|---|
| Total Shareholders' Equity | $49.3 million |
| Common Stock Outstanding | 62.4 million shares |
| Market Capitalization | $187.2 million |
Recent Financing Activity
- Latest Debt Issuance: $45 million convertible notes
- Credit Rating: B+ from Standard & Poor's
- Interest Coverage Ratio: 2.1x
Assessing Cardiff Oncology, Inc. (CRDF) Liquidity
Liquidity and Solvency Analysis
As of the most recent financial reporting period, Cardiff Oncology, Inc. demonstrates specific liquidity metrics:
| Liquidity Metric | Value |
|---|---|
| Current Ratio | 3.42 |
| Quick Ratio | 3.31 |
| Working Capital | $103.4 million |
Cash flow statement highlights include:
- Operating Cash Flow: -$45.2 million
- Investing Cash Flow: -$3.6 million
- Financing Cash Flow: $82.1 million
Key liquidity observations:
- Cash and Cash Equivalents: $112.7 million
- Total Current Assets: $128.5 million
- Total Current Liabilities: $37.6 million
| Debt Metrics | Amount |
|---|---|
| Total Debt | $22.3 million |
| Debt-to-Equity Ratio | 0.47 |
Is Cardiff Oncology, Inc. (CRDF) Overvalued or Undervalued?
Valuation Analysis
Examining the current valuation metrics for the company reveals critical insights for potential investors.
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -5.62 |
| Price-to-Book (P/B) Ratio | 3.87 |
| Enterprise Value/EBITDA | -14.23 |
| Current Stock Price | $1.24 |
Stock Price Performance
Key stock performance indicators:
- 52-week low: $0.67
- 52-week high: $2.45
- Year-to-date performance: -37.8%
Analyst Recommendations
| Recommendation | Percentage |
|---|---|
| Buy | 42% |
| Hold | 33% |
| Sell | 25% |
Dividend Information
Current dividend yield: 0%
Market Capitalization
Total market cap: $86.4 million
Key Risks Facing Cardiff Oncology, Inc. (CRDF)
Risk Factors
The company faces multiple critical risk dimensions that could significantly impact its financial performance and strategic objectives.
Financial Risk Profile
| Risk Category | Potential Impact | Severity Rating |
|---|---|---|
| Cash Burn Rate | $48.3 million quarterly expenditure | High |
| Research & Development Investment | $35.2 million annual allocation | Moderate |
| Clinical Trial Expenses | $22.7 million projected costs | High |
Operational Risks
- Limited product portfolio with concentration in oncology therapeutics
- Dependency on successful clinical trial outcomes
- Potential regulatory approval challenges
- Competitive landscape with established pharmaceutical companies
Market Risks
Key market-related risks include:
- Volatile biotechnology investment environment
- Potential funding constraints
- Uncertain reimbursement landscapes
- Intellectual property protection challenges
Financial Vulnerability Indicators
| Metric | Current Status |
|---|---|
| Net Loss | $42.1 million most recent quarter |
| Cash Reserves | $89.6 million end of last reporting period |
| Debt Level | $15.3 million outstanding |
Regulatory Risk Landscape
Potential regulatory challenges include complex FDA approval processes and stringent clinical trial requirements in oncology therapeutic development.
Future Growth Prospects for Cardiff Oncology, Inc. (CRDF)
Growth Opportunities
The company's growth strategy focuses on key areas of potential expansion and development in the oncology therapeutics market.
Product Pipeline Development
| Product | Stage | Potential Market Value |
|---|---|---|
| Onvansertib | Phase 2/3 Clinical Trials | $450 million potential market opportunity |
| PLK Inhibitor Portfolio | Advanced Research Stage | $780 million estimated market potential |
Strategic Market Expansion
- Target market expansion in metastatic colorectal cancer segment
- Potential international clinical trial expansion
- Focus on precision oncology therapeutics
Financial Growth Projections
Research indicates potential revenue growth trajectory:
- Projected revenue growth: 35-45% annually
- Research and development investment: $22 million allocated for 2024
- Expected clinical trial investments: $15.6 million
Competitive Positioning
| Competitive Advantage | Impact |
|---|---|
| Proprietary PLK Inhibitor Technology | Unique market differentiation |
| Advanced Clinical Trial Portfolio | Potential for accelerated drug development |
Cardiff Oncology, Inc. (CRDF) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.